Seth Harmon

CIK: 0001993300

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (14.3%)

Derivative conversions

Awards (A)4 (57.1%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

$Viridian Therapeutics, Inc.\DE logo$

VRDN

Viridian Therapeutics, Inc.\DE

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
2K shares at avg. $30.19$61K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Exercise(M)
Direct
6.3K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
2.1K shares at avg. $29.32$61K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
102.9K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Restricted Stock Units
Direct
20.6K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
150.4K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Restricted Stock Units
Direct
25.1K shares-

		Type	Shares	Price		Ownership
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	2,031	$30.19	$61,316	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Exercise(M)	6,267	-	$0	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	2,091	$29.32	$61,308	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	102,850	-	-	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	20,550	-	-	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	150,407	-	-	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	25,068	-	-	Direct

1-7 of 7 transactions

About Harmon Seth

Harmon Seth (SEC CIK 0001993300) files insider reports with the SEC as Chief Financial Officer of Viridian Therapeutics, Inc.\DE (VRDN).

Signal8 holds 4 ownership filings by Harmon Seth, all Form 4s, filed between Mar 4, 2025 and Mar 9, 2026. Those filings report 7 transactions, from Mar 3, 2025 to Mar 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Harmon Seth's filings is in WALTHAM, MA.

Recent filings by Harmon Seth

Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).
Mar 3, 2026: Option exercise of VRDN shares (Form 4, code M).
Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).
Mar 2, 2026: Grants or awards of VRDN derivative securities (2 lines, Form 4, code A).
Mar 3, 2025: Grants or awards of VRDN derivative securities (2 lines, Form 4, code A).

Other insiders filing for Viridian Therapeutics, Inc.\DE (VRDN)

Tousignant Jennifer, Chief Legal Officer
Tripuraneni Radhika, Chief Medical Officer
CAIN CHRISTOPHER W., Director
Ajer Jeffrey Robert, Director
Moses Jennifer K., Director
Gheuens Sarah, Director

How to read Form 4 transaction codes